1. Prevalence and Persistence of Maternal Dengue Neutralizing Antibodies in Infants From Central and Southern Thailand: A Retrospective Cohort Study.
- Author
-
Guignard A, Haguinet F, Wéry S, and Kerdpanich P
- Subjects
- Clinical Trials, Phase III as Topic, Dengue prevention & control, Dengue Vaccines administration & dosage, Female, Humans, Infant, Male, Prevalence, Randomized Controlled Trials as Topic, Retrospective Studies, Serogroup, Thailand, Antibodies, Neutralizing blood, Antibodies, Viral blood, Dengue Virus immunology, Immunity, Maternally-Acquired
- Abstract
Understanding maternal dengue virus (DENV) neutralizing antibody kinetics in infants remains timely to develop a safe and effective childhood immunization. This retrospective study evaluated the prevalence and persistence of maternal antibody titers against DENV serotypes 1 to 4 in 139 Thai infants at 2, 6, and 7 months of age, using serum samples collected in a vaccination trial ( http://clinicaltrials.gov ; NCT00197275). Neutralizing antibodies against all 4 DENV serotypes were detected in 87.8% and 22.9% of infants at 2 and 7 months, respectively. At 2 months, DENV-4 neutralizing antibody geometric mean titers were notably lower (80) compared with DENV-1 to DENV-3 (277-471). Our results corroborate previous findings that DENV-1 to DENV-4 maternal antibodies persist at 7 months despite titers decrease from 2 months onwards. As persisting maternal antibodies may inhibit immune responses in DENV-vaccinated infants, a comprehensive understanding of DENV antibody kinetics is required in the perspective of vaccine development for infants.
- Published
- 2019
- Full Text
- View/download PDF